• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Olema Pharmaceuticals Inc (NQ: OLMA )

    14.31 -0.14 (-0.97%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 428,573
    Open 14.44
    Bid (Size) 10.27 (1)
    Ask (Size) 15.12 (1)
    Prev. Close 14.45
    Today's Range 13.92 - 14.56
    52wk Range 7.780 - 17.79
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire

    Performance

    YTD
    +4.22%
    +4.22%
    1 Month
    +25.31%
    +25.31%
    3 Month
    +44.98%
    +44.98%
    6 Month
    +25.86%
    +25.86%
    1 Year
    +54.70%
    +54.70%

    More News

    Read More
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Olema Pharmaceuticals Inc. (NASDAQ: OLMA) Near the Top of Equities by Percentage Gain on 2/1
    Via Investor Brand Network
    Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Olema Oncology to Participate in Upcoming Investor Conferences in June
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
    From Olema Oncology
    Via GlobeNewswire
    OLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024
    Via InvestorPlace
    Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology to Participate in Upcoming Investor Conferences in May
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology to Participate in Upcoming Investor Conferences
    From Olema Oncology
    Via GlobeNewswire
    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Olema Oncology
    Via GlobeNewswire
    Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
    From Olema Oncology
    Via GlobeNewswire
    Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
    Via Investor's Business Daily
    Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
    From Olema Oncology
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.